Literature DB >> 12741076

[The impact of the Multicenter Automatic Defibrillator Implantation Trial II in a university hospital--do all patients with myocardial infarction and reduced left ventricular function need an implantable cardioverter-defibrillator?].

Peter Lercher1, Brigitte Rotman, Daniel Scherr, Wilfried Kraxner, Olef Luha, Werner Klein.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with coronary artery disease (CAD) and severely compromised left ventricular ejection fraction are at high risk to die from sudden cardiac death. The Multicenter Automatic Defibrillator implantation Trial II (MADIT II) shows a significant benefit of a cardioverter-defibrillator (ICD) therapy compared to standard treatment alone in this selected group of patients. The objective of the present study was to investigate the number of patients who will fulfil the MADIT II criteria and are candidates for prophylactic ICD implantation. METHODS AND MATERIAL: From January to December 2001 a total of 2653 patients underwent coronary angiography at our institution due to angina pectoris, positive exercise stress testing, pathological SPECT myocardial perfusion images, suspected dilated cardiomyopathy or ventricular arrhythmias. According to the MADIT II inclusion criteria patients with significant coronary artery disease (diameter stenosis > 50%), ejection fraction < 0.31% and previous myocardial infarction were included. Exclusion criteria were acute coronary syndromes, patients with ventricular tachyarrhythmias or an existing indication for ICD therapy, and patients with coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty within the past or following three months.
RESULTS: Out of 2653 patients 185 (7%) had an ejection fraction less than 0.31, 149 (5.6%) showed significant coronary artery stenosis and 70 (2.6%) patients fulfilled the MADIT II criteria. The mean age of these patients was 68 +/- 9 years, the left ventricular ejection fraction 24 +/- 6. In 37 patients an ICD system was implanted according to the existing guidelines. 70 patients met the MADIT II inclusion criteria, resulting in an increase of 189% of ICD implantations per year.
CONCLUSION: 2.6% out of 2653 patients who were referred to coronary angiography fulfilled the criteria of MADIT II. The expanding indication for ICD therapy will result in an annual increase of 70 (189%) prophylactic ICD implantations in our study population.

Entities:  

Mesh:

Year:  2003        PMID: 12741076     DOI: 10.1007/bf03040304

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  30 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Temporal and geographical trends in indications for implantation of cardiac defibrillators in Europe 1993-1998. Medtronic ICD System Investigators.

Authors:  X Copie; O Piot; M A Said; T Lavergne; J Ollitrault; L Guize; J Y Le Heuzey
Journal:  Pacing Clin Electrophysiol       Date:  2000-06       Impact factor: 1.976

3.  Task Force on Sudden Cardiac Death of the European Society of Cardiology.

Authors:  S G Priori; E Aliot; C Blomstrom-Lundqvist; L Bossaert; G Breithardt; P Brugada; A J Camm; R Cappato; S M Cobbe; C Di Mario; B J Maron; W J McKenna; A K Pedersen; U Ravens; P J Schwartz; M Trusz-Gluza; P Vardas; H J Wellens; D P Zipes
Journal:  Eur Heart J       Date:  2001-08       Impact factor: 29.983

4.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.

Authors: 
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

Review 5.  New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Authors:  H Klein; A Auricchio; S Reek; C Geller
Journal:  Am J Cardiol       Date:  1999-03-11       Impact factor: 2.778

6.  Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial.

Authors:  J Kron; J Herre; E G Renfroe; C Rizo-Patron; M Raitt; B Halperin; M Gold; B Goldner; M Wathen; B Wilkoff; A Olarte; Q Yao
Journal:  Am Heart J       Date:  2001-01       Impact factor: 4.749

7.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

8.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

9.  The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators.

Authors:  P J Best; D L Hayes; M S Stanton
Journal:  Pacing Clin Electrophysiol       Date:  1999-01       Impact factor: 1.976

10.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.

Authors:  J T Bigger; J L Fleiss; R Kleiger; J P Miller; L M Rolnitzky
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

View more
  2 in total

1.  [MADIT II--or how seriously do we take primary prevention of sudden cardiac death?].

Authors:  Helmut U Klein
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

2.  What evidence do we have to replace in-hospital implantable cardioverter defibrillator follow-up?

Authors:  P Brugada
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.